Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.

@article{Coltella2015SynergisticLE,
  title={Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.},
  author={Nadia Coltella and Roberta Valsecchi and Manfredi Ponente and Maurilio A. Ponzoni and R. M. Bernardi},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2015},
  volume={21 16},
  pages={
          3685-94
        }
}
PURPOSE Retinoic acid-arsenic trioxide (ATRA-ATO) combination therapy is the current standard of care for patients with acute promyelocytic leukemia (APL) carrying the oncogenic fusion protein PML-RARα. Despite the high cure rates obtained with this drug combination, resistance to arsenic is recently emerging. Moreover, patients with APL carrying the PLZF-RARα fusion protein are partially resistant to ATRA treatment. Hypoxia-inducible factor-1α (HIF-1α) activation has been recently reported in… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 5 times. VIEW TWEETS

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors

  • Y Xia, ChoiHK, K. Lee
  • Eur J Med Chem
  • 2012
Highly Influential
9 Excerpts

Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy

  • JH Park, TallmanMS
  • Oncology ;25:733–41. Clin Cancer Res;
  • 2015
1 Excerpt

Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure

  • J Ablain, K Rice, SoilihiH, A de Reynies, S Minucci, TheH. de
  • Nat Med
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…